Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three- and nine-month periods ending September 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Revenues for the third quarter 2008 were approximately $3,501,000 versus $3,520,000 for the comparable period a year ago. The Company reported a net loss for the third quarter of approximately ($3.4 million) or ($0.04) per share. This compares with a net loss of approximately ($3.0 million), or ($0.04) per share for the same period last year.

Revenues for the nine months ended September 30, 2008 were approximately $3,501,000 versus $3,520,000 for 2007. Reported net loss for the first nine months of 2008 was ($21.3 million), or ($0.26) per share as compared to ($18.6 million) or ($0.23) per share for 2007. As of September 30, 2008, EntreMed had cash and short-term investments of approximately $28 million.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "We have estimated that the royalty revenue from sales of Thalomid(R) for the 3rd quarter will be $3.5 million and we expect royalty revenue for the year to increase over 2007 with Celgene's acquisition of Pharmion Corporation. Research and development expenses for the third quarter declined versus the prior quarters in 2008 due in part to the decision made earlier in the year to discontinue the use of Panzem in oncology, but also impacted by a decreasing number of patients being treated with MKC-1 related to Phase 2 trials ini
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... CALGARY , June 30, 2015 /PRNewswire/ - ... ("Shareholders") of common shares of Resverlogix have approved ... to Eastern Capital Limited of 5,600,000 units at ... Private Placement"), each unit being comprised of one ... for aggregate proceeds of approximately CAD$15 million; and ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... provide new insights on mechanics of fecal microbiota transplantation in C. difficile patients. ... the microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment for ...
(Date:6/30/2015)... 2015  The University of California, San Diego,s ... UC San Diego Extension announced their third annual ...  12 – 14, 2015, at UC San Diego ... an intense exposure to best practices and the ... to biologists, process engineers and business executives planning ...
(Date:6/30/2015)... ... 2015 , ... Smarter Alloys today announced a final round ... allows orthodontists to simultaneously apply different forces to different teeth. The additional case ... about taking SmartArch one step closer to commercial availability for orthodontists and dentists,” ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2
... Sees Significant Environmental Benefits on His Farm , ... ... planted genetically modified (GM) herbicide-tolerant canola crops in the mid-1990s. ... percent of the canola hectares nationwide to GM canola., , , ...
... (Nasdaq:,SSRX), a leading China-based biotechnology company focused on ... results of the shareholder votes at its 2008 ... 2008 (Friday) at 10:00 a.m.,(Beijing time)., At ... Lou,Liping Xu, Bin Huang, Lawrence S. Wizel, Mingde ...
... ATLANTA, Sept. 15 Presbyterian Cancer Center - ... and Texas Oncology,PA, recently installed an Elekta Infinity ... Volumetric Modulated Arc Therapy (VMAT).,Elekta Infinity is the ... the Center to offer patients shortened treatment times ...
Cached Biology Technology:Genetically Modified Canola Plantings Reach 90 Percent in Canada 2Genetically Modified Canola Plantings Reach 90 Percent in Canada 3Presbyterian Cancer Center to Offer Cancer Patients High-End VMAT Treatments With the Installation of Elekta Infinity 2Presbyterian Cancer Center to Offer Cancer Patients High-End VMAT Treatments With the Installation of Elekta Infinity 3
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... N.C. -- Some primates have evolved big brains because ... an advantage that outweighs the demands of extra years ... from Duke University and the University of Zurich have ... compared key benchmarks in the development of 28 different ...
... comprehensive book of essays, highlighting the most pressing conservation issues ... Society. The essays, penned by top ... animals and people; and the challenge of saving wildlife in ... A Global Portrait of Wildlife, Wildlands, and Oceans, the book ...
... a heart attack may now be possible using only a ... team led by researchers at The University of Texas at ... for Dental Research. The nano-bio-chip assay could some day ... ambulance, at the dentists office or at a neighborhood drugstore, ...
Cached Biology News:Slowly-developing primates definitely not dim-witted 2Slowly-developing primates definitely not dim-witted 3Wildlife Conservation Society releases definitive 'state of the wild' 2Saliva can help diagnose heart attack, study shows 2
Applications: ISH...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
Biology Products: